Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in share interests for specific individuals following the re-investment of dividends paid on January 8, 2009. Shares were purchased at a price of £12.88 per share on January 13, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a procedural disclosure regarding the GlaxoSmithKline Annual Investment Plan.
Important Facts for Investors
- Directors and managers increased their shareholdings via dividend re-investment.
- The transaction price was £12.88 per share on January 13, 2009.
- Specific share increases included: Mr A P Witty (111), Dr M M Slaoui (246), Mr M Dunoyer (119), Dr D Pulman (182), and Ms C Thomas (46).
- No financial performance data is included in this specific filing.